Compare LBRDK & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRDK | UTHR |
|---|---|---|
| Founded | 2014 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 20.3B |
| IPO Year | N/A | 1999 |
| Metric | LBRDK | UTHR |
|---|---|---|
| Price | $47.64 | $488.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $495.08 |
| AVG Volume (30 Days) | ★ 1.2M | 424.3K |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 1.38 | ★ 16.08 |
| EPS | 5.51 | ★ 26.38 |
| Revenue | $1,016,000,000.00 | ★ $3,128,400,000.00 |
| Revenue This Year | $8.37 | $13.64 |
| Revenue Next Year | $2.91 | $5.78 |
| P/E Ratio | ★ $5.70 | $18.55 |
| Revenue Growth | ★ 306.40 | 13.50 |
| 52 Week Low | $44.63 | $266.98 |
| 52 Week High | $104.00 | $492.62 |
| Indicator | LBRDK | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 68.10 |
| Support Level | $44.88 | $470.13 |
| Resistance Level | $46.77 | $492.62 |
| Average True Range (ATR) | 1.42 | 10.72 |
| MACD | 0.54 | -0.53 |
| Stochastic Oscillator | 82.05 | 89.55 |
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.